Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Chimerix Secures FDA Priority Review For Dordaviprone, Advancing Potential First Treatment For Recurrent H3 K27M-Mutant Diffuse Glioma

Author: Benzinga Newsdesk | February 18, 2025 07:33am

Potential First Approval for Patients with Recurrent H3 K27M-mutant Diffuse Glioma
PDUFA Target Action Date of August 18, 2025
No Advisory Committee Meeting Currently Planned to Discuss Application

Posted In: CMRX